Kihara James 4
4 · ACADIA PHARMACEUTICALS INC · Filed Jun 29, 2026
Research Summary
AI-generated summary of this filing
ACADIA (ACAD) Accounting Officer James Kihara Sells 11,421 Shares
What Happened
James Kihara, Principal Accounting Officer at ACADIA Pharmaceuticals (ACAD), reported the sale of 11,421 shares in an open-market/private sale on June 26, 2026. The reported weighted-average price was $26.08 per share, for total proceeds of approximately $297,912. This was a sale (S), not a purchase.
Key Details
- Transaction date: 2026-06-26 (reported on Form 4 filed 2026-06-29). Filing was within the required two-business-day window.
- Price: weighted average $26.08; shares were sold in multiple trades at prices ranging from $25.88 to $26.265 (per footnote).
- Shares sold: 11,421; total reported proceeds ≈ $297,912.
- Shares owned after transaction: not provided in the material you supplied.
- Footnotes: Transaction occurred under a Rule 10b5-1 trading plan adopted by Kihara on December 9, 2025 (F1). F2 notes the weighted-average price and that detailed per-trade prices are available on request.
Context
This sale was executed under a pre-established 10b5-1 plan, which typically means the trades were pre-planned and may be routine rather than a real-time signal about company prospects. Sales are common for insiders to diversify or meet cash needs; purchases are generally considered more informative about insider sentiment. The filing appears timely.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-06-26$26.08/sh−11,421$297,912→ 13,088 total
Footnotes (2)
- [F1]Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 9, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.88 to $26.265, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.